Pfizer Inc (PFE)

$23.67 -0.37 (-1.54%)
Market Cap 137.01B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.08
Forward PE 8.28
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 57,957,600
Avg Vol 39,182,297
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 2%
Beta 0.34
Analysts Sell
Price Target $29.24

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 1:48 AM
$SLS $PFE $BMY $ABBV $MRK 5. Fast Track Designation • Indications: AML, MPM, and MM. • Details: Expedites the FDA review and development process for drugs treating serious conditions that fill unmet medical needs. 6. 3 Priority Review Vouchers worth $450 Million Dollars at current market rates for PRV’s for big pharmaceutical suitors. 7. 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL phase 3 readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth= $240.00+ after Bidding War. REGAL phase 3 Paradigm Shifting data is about to delivers perhaps the most consequential and contested acquisition in Biotechnology sector has seen in a generation. ***Change of Control filed today, all the pieces are now in place. ✌️🙏❤️‍🩹
1 · Reply
markbrogan
markbrogan Jun. 26 at 1:13 AM
$PFE this was a well coordinated and orchestrated short. The stock biunce back very soon.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 26 at 12:07 AM
$PFE Share Price: $23.68 Contract Selected: Jul 17, 2026 $25 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.14 – $0.17 Potential Upside: 74% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
simonds
simonds Jun. 25 at 11:29 PM
$PFE Looks like the algorithms instruct buying in the morning in order to suck people into buying and then dump the large firms shares at a better price.
0 · Reply
Willieberich
Willieberich Jun. 25 at 10:54 PM
$PFE I can't sit on this twits back and forth garbage .i know what's happening here ..don't get your info on twits .pothead is a shorter hedge fund
0 · Reply
Willieberich
Willieberich Jun. 25 at 10:51 PM
$PFE someone let pothead I'm still here! I will be buying as this goes down small at 1st .but holding some of my position .good luck people .
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 25 at 10:46 PM
$PFE read the ex divy date wrong today and rolled my puts I sold for the wrong price 🫩
1 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 25 at 10:06 PM
$PFE So far its really only failed people who's immune systems were already shot to hell with chemo. Im siding more with the optimism from Pfizer. It was given as a hail Mary last ditch effort and couldn't pull a miracle but that doesn't mean it cant do what its designed to do and so far we dont have those results. Would have been great if it could have worked magic on those people but it sounds like Pfizer never really expected it to. It was just a long shot hope and you might as well give it a try. Am I off base here?
0 · Reply
Woodmont
Woodmont Jun. 25 at 10:04 PM
$PFE Most major pharmaceutical companies companies share price has risen between 10-40% in the last year, LLY, JNJ, BIIB, JAZZ, MRK you get the point and yet this crap has gone nowhere but down, that should tell us something number one the street hates current management, number 2 they should be buying back shares cut the divy and use the money to buy back shares, the current CEO tells us nothing about what he is doing to improve shareholder value he has said nothing, he must go bring in someone with some vision
1 · Reply
simonds
simonds Jun. 25 at 9:57 PM
$PFE Borla is simply not qualified to be ceo. He is a veterinarian who does not have the proper experience running a large pharma company. This fiasco should be more on the board of directors for hiring him and continue to let him run this once quality company into the ground. Bourla is in way over his head.
0 · Reply
Latest News on PFE
Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 1 day ago

Pfizer Declares Third-Quarter 2026 Dividend

Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer

2026-06-24T18:20:21.000Z - 1 day ago

Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 2:10 PM EDT - 1 day ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

FDA approves Pfizer’s Ibrance combo for metastatic breast cancer

2026-06-24T15:25:12.000Z - 1 day ago

FDA approves Pfizer’s Ibrance combo for metastatic breast cancer

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 1 day ago

Pfizer dismissed from US states' drug price-fixing lawsuit

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 12:10 PM EDT - 2 days ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 23, 2026, 10:00 AM EDT - 2 days ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 3 days ago

Pfizer's experimental drug misses main goal of lung cancer trial

Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint

2026-06-22T20:33:17.000Z - 3 days ago

Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 4:30 PM EDT - 3 days ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

Jun 22, 2026, 2:32 PM EDT - 3 days ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Pfizer (PFE) Shares Sink After Surprise CFO Exit

2026-06-18T18:35:11.000Z - 7 days ago

Pfizer (PFE) Shares Sink After Surprise CFO Exit

Pfizer reaffirms all components of FY26 guidance

2026-06-18T17:30:31.000Z - 7 days ago

Pfizer reaffirms all components of FY26 guidance

Pfizer CFO Dave Denton to step down, Cecile Guegan named interim CFO

2026-06-18T10:52:33.000Z - 7 days ago

Pfizer CFO Dave Denton to step down, Cecile Guegan named interim CFO

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 7 days ago

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 7 days ago

Pfizer Announces Chief Financial Officer Transition

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 10, 2026, 7:56 AM EDT - 15 days ago

Pfizer CEO warns German investment at risk over drug pricing policies

Pfizer upgraded to Sector Perform from Underperform at RBC Capital

2026-06-09T21:05:52.000Z - 16 days ago

Pfizer upgraded to Sector Perform from Underperform at RBC Capital

Pfizer upgraded to Sector Perform at RBC Capital amid more balanced risk-reward

2026-06-09T21:05:12.000Z - 16 days ago

Pfizer upgraded to Sector Perform at RBC Capital amid more balanced risk-reward

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 16 days ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 16 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 16 days ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 17 days ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Pfizer says FDA approves expanded indication for Hympavzi

2026-06-08T10:51:57.000Z - 17 days ago

Pfizer says FDA approves expanded indication for Hympavzi

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 17 days ago

US FDA approves Pfizer's bleeding disorder drug for children

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 8, 2026, 6:45 AM EDT - 17 days ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer presents results from Phase 2b studies of berobenatide

2026-06-07T22:00:49.000Z - 18 days ago

Pfizer presents results from Phase 2b studies of berobenatide

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 19 days ago

Pfizer Transcript: Study update

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 19 days ago

Pfizer Slides: Study update

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:06 AM EDT - 19 days ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 6, 2026, 9:00 AM EDT - 19 days ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 10:00 AM EDT - 21 days ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Jun 4, 2026, 6:40 AM EDT - 21 days ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 22 days ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jun 1, 2026, 10:00 AM EDT - 24 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026, 8:00 AM EDT - 25 days ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Mailbag: A Follow-Up on Pfizer & Other Questions

May 30, 2026, 9:22 AM EDT - 26 days ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026, 8:00 AM EDT - 26 days ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29, 2026, 8:00 AM EDT - 27 days ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 11:10 PM EDT - 27 days ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:19 PM EDT - 4 weeks ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 4 weeks ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 4 weeks ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 27, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 9:00 AM EDT - 5 weeks ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:08 AM EDT - 5 weeks ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20, 2026, 5:05 AM EDT - 5 weeks ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 18, 2026, 8:00 AM EDT - 5 weeks ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

May 14, 2026, 2:22 PM EDT - 6 weeks ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 13, 2026, 6:45 AM EDT - 6 weeks ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 7 weeks ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 7 weeks ago

Pfizer CEO on AI-designed molecule, and race to use new tech

3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 7 weeks ago

3 Dividend Stocks for May 2026

SYY WSO

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings Call Transcript: Q1 2026

Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings release: Q1 2026

Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Quarterly report: Q1 2026

Pfizer Slides: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Slides: Q1 2026

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 7 weeks ago

Pfizer Posts Better-Than-Expected Revenue, Profit

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:23 AM EDT - 7 weeks ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

May 5, 2026, 7:06 AM EDT - 7 weeks ago

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

Why selling these 3 dividend stocks could be a mistake

May 5, 2026, 7:05 AM EDT - 7 weeks ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

May 5, 2026, 6:55 AM EDT - 7 weeks ago

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

May 5, 2026, 6:51 AM EDT - 7 weeks ago

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

May 5, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 7 weeks ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

Pfizer's blood cancer drug meets main goal in late-stage trial

Apr 29, 2026, 7:42 AM EDT - 2 months ago

Pfizer's blood cancer drug meets main goal in late-stage trial

SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 1:48 AM
$SLS $PFE $BMY $ABBV $MRK 5. Fast Track Designation • Indications: AML, MPM, and MM. • Details: Expedites the FDA review and development process for drugs treating serious conditions that fill unmet medical needs. 6. 3 Priority Review Vouchers worth $450 Million Dollars at current market rates for PRV’s for big pharmaceutical suitors. 7. 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL phase 3 readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth= $240.00+ after Bidding War. REGAL phase 3 Paradigm Shifting data is about to delivers perhaps the most consequential and contested acquisition in Biotechnology sector has seen in a generation. ***Change of Control filed today, all the pieces are now in place. ✌️🙏❤️‍🩹
1 · Reply
markbrogan
markbrogan Jun. 26 at 1:13 AM
$PFE this was a well coordinated and orchestrated short. The stock biunce back very soon.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 26 at 12:07 AM
$PFE Share Price: $23.68 Contract Selected: Jul 17, 2026 $25 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.14 – $0.17 Potential Upside: 74% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
simonds
simonds Jun. 25 at 11:29 PM
$PFE Looks like the algorithms instruct buying in the morning in order to suck people into buying and then dump the large firms shares at a better price.
0 · Reply
Willieberich
Willieberich Jun. 25 at 10:54 PM
$PFE I can't sit on this twits back and forth garbage .i know what's happening here ..don't get your info on twits .pothead is a shorter hedge fund
0 · Reply
Willieberich
Willieberich Jun. 25 at 10:51 PM
$PFE someone let pothead I'm still here! I will be buying as this goes down small at 1st .but holding some of my position .good luck people .
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 25 at 10:46 PM
$PFE read the ex divy date wrong today and rolled my puts I sold for the wrong price 🫩
1 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 25 at 10:06 PM
$PFE So far its really only failed people who's immune systems were already shot to hell with chemo. Im siding more with the optimism from Pfizer. It was given as a hail Mary last ditch effort and couldn't pull a miracle but that doesn't mean it cant do what its designed to do and so far we dont have those results. Would have been great if it could have worked magic on those people but it sounds like Pfizer never really expected it to. It was just a long shot hope and you might as well give it a try. Am I off base here?
0 · Reply
Woodmont
Woodmont Jun. 25 at 10:04 PM
$PFE Most major pharmaceutical companies companies share price has risen between 10-40% in the last year, LLY, JNJ, BIIB, JAZZ, MRK you get the point and yet this crap has gone nowhere but down, that should tell us something number one the street hates current management, number 2 they should be buying back shares cut the divy and use the money to buy back shares, the current CEO tells us nothing about what he is doing to improve shareholder value he has said nothing, he must go bring in someone with some vision
1 · Reply
simonds
simonds Jun. 25 at 9:57 PM
$PFE Borla is simply not qualified to be ceo. He is a veterinarian who does not have the proper experience running a large pharma company. This fiasco should be more on the board of directors for hiring him and continue to let him run this once quality company into the ground. Bourla is in way over his head.
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 25 at 9:50 PM
$PFE After the results, artificial intelligence gives SV a 35% chance of still being a blockbuster. Thats not too bad I guess
1 · Reply
simonds
simonds Jun. 25 at 9:46 PM
$PFE Loser management, including the board of directors
0 · Reply
simonds
simonds Jun. 25 at 9:45 PM
$PFE Management Stinks, they overpay for useless companies; they make very poor decisions in all aspects of running a pharma company.
0 · Reply
Mexu
Mexu Jun. 25 at 9:35 PM
$PFE Denton was headhunted from Pfizer. However, he can’t save Nike as Nike needs trendsetter, not a finance guy
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Jun. 25 at 9:30 PM
$PFE - Oh yeah, Pfizer, the pharma ‘giant’
1 · Reply
simonds
simonds Jun. 25 at 9:30 PM
$PFE Charlie represents the shareholders, Lucy represents Borla and the board of directors.
0 · Reply
ItsCarRamRod
ItsCarRamRod Jun. 25 at 9:22 PM
$PFE so come back around the year 2029 and bourla will make a difference, ROFL.
0 · Reply
Guntz
Guntz Jun. 25 at 9:19 PM
$PFE Just give me $25
1 · Reply
JoeS11
JoeS11 Jun. 25 at 9:07 PM
$PFE This company literally only exists to make another pharm company sharehders rich at the expense of their own shareholders.
2 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 25 at 9:04 PM
$PFE Ive lost enough money here to buy 80,000 helium balloons... thats enough balloons to carry a 1800lb moose across a small sea... and that's just depressing
4 · Reply
tmgolf123
tmgolf123 Jun. 25 at 9:01 PM
$PFE why is this so bad
2 · Reply
BullMaven
BullMaven Jun. 25 at 8:57 PM
$PFE gladly added 250 today
0 · Reply